EP Patent

EP4406593A3 — Use of long-acting glp-1 peptides

Assigned to Novo Nordisk AS · Expires 2024-10-23 · 2y expired

What this patent protects

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

USPTO Abstract

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

Drugs covered by this patent

Patent Metadata

Patent number
EP4406593A3
Jurisdiction
EP
Classification
—
Expires
2024-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.